December 12, 2017 9:13pm
BLUE had closed down -$10.85 or -5.38% to $190.95
bluebird bio (BLUE), has commenced an underwritten public offering of 3,243,244 common stock priced at $185.00
bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares (496,486 shares) of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by bluebird bio.
Goldman Sachs & Co. LLC, B of A Merrill Lynch, J.P. Morgan Securities LLC and Cowen are acting as joint book-running managers of the proposed offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Expected ... as the jump in the day's range of $190.60 to $203.60 is NOT an oppurtunity to lose ...
